Drs. Dietrich and Holloway continue sharing their insights into the pivotal role of HER2 positivity in gynecologic cancers. They discuss how HER2, a well-known biomarker in breast cancer, is increasingly recognized for its significance in other gynecologic malignancies, including ovarian and endometrial cancers.
